WallStreetZenWallStreetZen

NASDAQ: MTVA
Metavia Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MTVA

Based on 2 analysts offering 12 month price targets for Metavia Inc

Min Forecast
$3.00+252.94%
Avg Forecast
$7.50+782.35%
Max Forecast
$12.00+1,311.76%

Should I buy or sell MTVA stock?

Based on 2 analysts offering ratings for Metavia Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MTVA stock forecasts and price targets.

MTVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-04
lockedlocked$00.00+00.00%2025-05-19

1 of 1

Forecast return on equity

Is MTVA forecast to generate an efficient return?

Company
-1,174.59%
Industry
247.01%
Market
230.21%
MTVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MTVA forecast to generate an efficient return on assets?

Company
-612.4%
Industry
98.7%
MTVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MTVA earnings per share forecast

What is MTVA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.07
Avg 2 year Forecast
-$0.78
Avg 3 year Forecast
-$0.84

MTVA revenue forecast

What is MTVA's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

MTVA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MTVA$1.00$7.50+650.00%Strong Buy
GDTC$2.11N/AN/A
ENLV$1.00$10.00+900.00%Strong Buy
DARE$1.84$8.00+334.78%Strong Buy
NRXS$2.54$7.00+175.59%Buy
View Top Biotech Stocks

Metavia Stock Forecast FAQ

Is Metavia Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MTVA) stock is to Strong Buy MTVA stock.

Out of 2 analysts, 1 (50%) are recommending MTVA as a Strong Buy, 1 (50%) are recommending MTVA as a Buy, 0 (0%) are recommending MTVA as a Hold, 0 (0%) are recommending MTVA as a Sell, and 0 (0%) are recommending MTVA as a Strong Sell.

If you're new to stock investing, here's how to buy Metavia stock.

What is MTVA's earnings growth forecast for 2025-2027?

(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.

Metavia's earnings in 2025 is -$18,491,000.On average, 6 Wall Street analysts forecast MTVA's earnings for 2025 to be -$25,964,249, with the lowest MTVA earnings forecast at -$28,456,623, and the highest MTVA earnings forecast at -$22,053,883. On average, 6 Wall Street analysts forecast MTVA's earnings for 2026 to be -$18,794,438, with the lowest MTVA earnings forecast at -$26,559,515, and the highest MTVA earnings forecast at -$8,791,064.

In 2027, MTVA is forecast to generate -$20,239,047 in earnings, with the lowest earnings forecast at -$25,848,100 and the highest earnings forecast at -$8,384,541.

What is MTVA's revenue growth forecast for 2025-2027?

(NASDAQ: MTVA) Metavia's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.

Metavia's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast MTVA's revenue for 2025 to be $0, with the lowest MTVA revenue forecast at $0, and the highest MTVA revenue forecast at $0. On average, 6 Wall Street analysts forecast MTVA's revenue for 2026 to be $0, with the lowest MTVA revenue forecast at $0, and the highest MTVA revenue forecast at $0.

In 2027, MTVA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is MTVA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MTVA) forecast ROA is -612.4%, which is lower than the forecast US Biotechnology industry average of 109.29%.

What is MTVA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MTVA price target, the average MTVA price target is $7.50, with the highest MTVA stock price forecast at $12.00 and the lowest MTVA stock price forecast at $3.00.

On average, Wall Street analysts predict that Metavia's share price could reach $7.50 by Sep 4, 2026. The average Metavia stock price prediction forecasts a potential upside of 650% from the current MTVA share price of $1.00.

What is MTVA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MTVA) Metavia's current Earnings Per Share (EPS) is -$1.49. On average, analysts forecast that MTVA's EPS will be -$1.07 for 2025, with the lowest EPS forecast at -$1.18, and the highest EPS forecast at -$0.91. On average, analysts forecast that MTVA's EPS will be -$0.78 for 2026, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.36. In 2027, MTVA's EPS is forecast to hit -$0.84 (min: -$1.07, max: -$0.35).

What is MTVA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MTVA) forecast ROE is -1,174.59%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.